Neuroprotective Strategies in Neural Grafting
互联网
Control (% Survival) |
Treatment (% Survival) |
Notes |
|
---|---|---|---|
GDNF |
|||
Rosenblad et al., 1996 a |
9.7 |
37.4 |
|
Sinclair et al., 1996 b |
0.7 |
8.1 |
|
Sinclair et al., 1996 a |
1.0 |
13.0 |
|
Granholm et al., 1997 |
2.5-fold increase |
No absolute quantification |
|
Apostolides et al., 1997 a |
2.4 |
1.6 |
Fresh |
Apostolides et al., 1997 a |
2.6 |
3.4 |
Hibernated 6 d |
Mehtaetal., 1998 a |
1.6 |
2.0 |
Hibernated 6 d |
Sautter et al., 1998 b |
5.1 |
12.9 |
|
Yureketal., 1998 b |
1.9 |
5.8 |
|
bFGF |
|||
Mayer et al., 1993 a |
0.9 |
1.6 |
3-wk survival |
Mayer et al., 1993 b |
1.0 |
2.7 |
9-wk survival |
Takayama et al., 1995 a |
6.3 |
87.5 |
|
Takayama et al., 1995 b |
1.5 |
20.0 |
|
Zeng et al., 1996 a |
10.9 |
25.0 |
|
GDNF + bFGF + IGF |
|||
Zawada et al., 1998 |
8.2 |
12.7 |
24-h survival |
Zawada et al., 1998 |
4.1 |
6.6 |
7-d survival |
Lazaroids |
|||
Nakao et al., 1994 b |
15.7 |
41.4 |
|
Grasbon-Frodl et al., 1996 b |
b 6.5 |
14.0 |
Hibernated 8 d |
Bj�rklund et al., 1997 b |
0.9 |
2.3 |
Solid grafts in anterior eye chamber |
Karlsson et al., 1999 b |
6.4 |
10.9 |
|
Calcium antagonists Finger and Dunnett, 1989 |
Increased graft volume |
Dopamine neurons not quantified |
|
Kaminski Schierle et al., 1999 b |
8.2 |
21.5 |
|
Caspase inhibitors Schierle et al., 1999 b |
10 |
36 |